Dose-Related Effectiveness of Andexanet Alfa for Reversal of Apixaban Anticoagulation in a Porcine Polytrauma Model

Background Andexanet alfa (andexanet) is a reversal agent for use in patients with life-threatening or uncontrolled bleeding treated with oral factor Xa (FXa) inhibitors. There are limited data on the dose-response relationship of andexanet and FXa inhibitor-related bleeding. Objective The aim of this study was to assess the dose-related effectiveness of andexanet in reducing blood loss, improving survival, and reversing apixaban anticoagulation in a porcine polytrauma model. Methods Apixaban was given orally to 40 male pigs for 3 days at a dose of 20mg/d. On day 3, following bilateral femur fractures and blunt liver injury, animals (n - 8/ group) received andexanet ( 250-mg bolus, 250-mg bolusthorn300-mg 2-hour infusion, 500-mg bolus, or 500-mg bolusthorn600-mg 2-hour infusion) or vehicle (control). Total blood loss was the primary endpoint. Coagulation parameters were assessed for 300minutes or until death. Data were analyzed with a mixed-model analysis of variance. Results Administration of 250- mg bolusthorn300-mg infusion, andexanet 500-mg bolus, and 500-mg bolusthorn600-mg infusion significantly decreased total blood loss by 37, 58, and 61%, respectively (all p< 0.0001), with 100% survival. Andexanet 250-mg bolus was ineffective in reducing total blood loss (6%) and mortality (63% survival) versus controls. Andexanet 500-mg bolus +/- infusion neutralized anti-FXa activity to less than 50 ng/mL. Andexanet neutralization of thrombin generation and thromboelastometry parameters was dose and infusion time dependent. Conclusion In a porcine polytrauma model with major bleeding on apixaban, andexanet dose dependently decreased anti-FXa activity. Lower anti- FXa levels (<50 ng/mL) with andexanet 500-mg bolus coproduct infusion were correlated with 60% less blood loss and 100% survival versus controls.